Aquinox Pharma (AQXP) Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome Failed to Meet Primary Endpoint
Tweet Send to a Friend
Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ: AQXP), today announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
